Don’t bother saving, Ben Bernanke told Congress one Wednesday, echoing a message the Fed has been sending to the middle class for 15 years. The zero interest rate policy (ZIRP) has been discouraging responsible saving and fueling a massive increase in Wall Street borrowing and speculating. And its unlikely to end anytime soon.
The impact on your wallet is very real. Banks have reduced interest rates on deposits dramatically, leaving savers no option but to gamble on stocks or lose money to inflation every year.
Check out this chart, courtesy of Zero Hedge. It shows how the Fed has been punishing responsible savers over the last decade. The data set is as follows:
1. Total savings in billions (blue line)
2. Average interest rates on savings deposits FRED (M2OWN) (green line)
3. Interest income on savings in billions (red line)
From 1964 to present, the chart shows a steady rise in total savings deposits, with significant growth after 2000. After peaking at 10% in the 1980s, average interest paid on savings declined steadily. It now hovers near zero. Meanwhile, despite the massive increase in the amount of savings by bank customers, income from savings has remained stagnant over the past decade.
Of course, earlier trends parted around the year 2000, when the ZIRP era began. Since then, Fed policy has been focused entirely on making that unemployment number budge, at the expense of encouraging savings.
Even though the Fed’s asset purchases may decline after 2014, ZIRP will likely continue long after.
Despite the punishment savers are taking, the track record for “stimulus” isn’t great. As Daily Reckoning contributor Dan Amoss said earlier this year: “The number you need to remember is zero. Zero is where central banks will peg interest rates for several years into the future. Zero is the number of times in recorded history that the QE/ZIRP policies in place worldwide have boosted any economy to escape velocity…”
The days of parking your life savings with a bank may be gone for good.
For The Daily Reckoning
P.S. Readers of The Daily Reckoning get loads of tips on how to protect your assets from ZIRP and inflation. Click here now to sign up for free.
Despite what most mainstream media outlets will tell you, it is impossible for a central bank to force a "self-sustaining recovery"... no matter how much money it prints. Today, Dan Amoss examines the far-reaching consequences of such short-sighted actions, and who - if anyone - stands to benefit. Read on...
Jason M. Farrell is a writer based in Washington D.C. and Baltimore, MD. Before joining Agora Financial in 2012 he was a research fellow at the Center for Competitive Politics, where his work was cited by the New York Post, Albany Times Union and the New York State Senate. He has been published at United Liberty, The Federalist, The Daily Caller and LewRockwell.com among many other blogs and news sites.
Chuck Butler discusses the stimulus in China and what he sees are the differences, plus details as Greece arrives in Brussels with their latest proposal for an agreement. All that and more in today's Daily Pfennig...
Jim Rickards updates his "There Will Be No 'Grexit'" thesis as two stories dominate global financial headlines. Find out why global capital markets are a tale of two crises.
No, Greece won't wreck the financial world. And neither will China. But we're still on alert... Dave Gonigam reports...
Egon von Greyerz reports on the approaching financial implosion of banks that threatens to drag the entire financial system down with it....
The most promising and exciting advance in all the history of medicine is upon us, and yet it is actually not new at all — it’s as old as humans. The advance? Our immune systems. Stephen Petranek has more on how immunotherapy could change the way we treat cancer
With the oil sector cruising in low gear since last year’s price collapse, should you be investing in oil companies? Yes, according to our friends at Sprott, Henry and Rick — especially if you look at mid-stream companies, which move oil from point A to point B. Since oil moves no matter the price, they make money no matter the price!
Just a few days ago, I noticed that 70 biotech stocks were in the green on the week -- a week where almost every single S&P component was in the red on Monday afternoon. So we hitched our wagon to health care stocks. And these stocks have remained strong in the face of a hurricane of negative news hitting the airwaves.